Cordex Pharma Files ATPace Formulation Patent
... acute management of paroxysmal supraventricular tachycardia (PSVT) as well as a diagnostic test for the ... have been clinically used to terminate tachycardia in certain cases. "We are very pleased with ... for the treatment of paroxysmal supraventricular tachycardia in 2009. Cordex's CDP-1050 is also expected to ...Cordex Pharma Submits to the FDA an Amended Special Protocol Assessment for ATPace
... have been clinically used to terminate tachycardia in certain cases. About Cordex Pharma, Inc. ... for the treatment of paroxysmal supraventricular tachycardia in 2009. Cordex's CDP-1050 is also expected to ... for the treatment of paroxysmal supraventricular tachycardia and the anticipated results of the trial, the ...Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers
... a Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia in 2009. Cordex's CDP-1050 is also expected to commence a Phase 2 clinical ... Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia and the anticipated results of the trial and CDP-1050's expected ...Cordex Pharma Sets Fourth Quarter 2008 Program Update Call
... a Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia in 2009. Cordex's CDP-1050 is also expected to commence a Phase 2 clinical ... Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia and the anticipated results of the trial, and CDP-1050's expected ...Duska Therapeutics Receives Comments From FDA on Phase 3 ATPace(TM) Protocol Synopsis
... of a frequent cardiac arrhythmia called paroxysmal supraventricular tachycardia (PSVT). On April 16, 2008, Duska met with the FDA and confirmed that a ... Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia and Duska's CDP-1050 is expected to commence a Phase 2 clinical trial for ...Cordex Receives Special Protocol Assessment Approval from FDA for ATPace(TM)
... clinical trials evaluating its lead product ATPace(TM) as an antiarrhytmic drug for the acute treatment of patients with paroxysmal supraventricular tachycardia (PSVT) under the Special Protocol Assessment (SPA) process. ATPace(TM) is a novel stable liquid formulation of adenosine 5'-triphosphate (ATP). ...Expert consensus on catheter ablation of ventricular arrhythmias
... tachycardias that originate from the epicardial surface of the heart. The delineation of the relation between cardiac anatomy and focal ventricular tachycardia origins in the right and left ventricular outflow tracts and papillary muscles. ...Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009
... daily clinical practice and scientific discovery. This year we are seeing an important increase in utilization for applications such as ventricular tachycardia and navigation of the unpredictable anatomy associated with congenital heart disease. Our customers report that magnetic navigation is uniquely ...Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures
... for the treatment of paroxysmal supraventricular tachycardia (PSVT). Under the agreement, a portion of Cato's ... have been clinically used to terminate tachycardia in certain cases. Cordex has submitted its ... for the treatment of paroxysmal supraventricular tachycardia in 2009. Cordex's CDP-1050 is also expected to ...Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
... a Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia early in 2009. Cordex's CDP-1050 is also expected to commence a Phase 2 ... Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia and the anticipated results of the trial, CDP-1050's expected commencement ...Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
... atrio-ventricular nodal conduction, have been clinically used to terminate tachycardia in certain cases. "The request for a SPA represents a significant ... Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia in Q1 2009. Duska's CDP-1050 is expected to commence a Phase 2 clinical ...Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
... serious health disorders. In addition to the long-term health risks, elevated acetaldehyde levels produce acute symptoms, including facial flushing, tachycardia (rapid heart rate), headache, nausea and dizziness. Although ALDH2 deficient people suffer from unpleasant reactions and face long-term health ...Chilli II Cooled Ablation Catheters
Description:... performance of the Boston Scientific Blazer(R) catheter platform. Cooled cardiac ablation is a recent advancement in the treatment of ventricular tachycardia (VT) using radio frequency (RF) energy. VT is a serious cardiac arrhythmia characterized by heart rates above 100 beats per minute. The Boston ...Targeted drug therapy prevents exercise-induced arrhythmias
... risk for sudden death, but ongoing arrhythmias can result in frequent stressful shocks. The Dutch patient, for example, experienced ventricular tachycardia and ICD shocks whenever he got out of bed, Knollmann said. Defibrillator therapy also can be problematic for pediatric patients (CPVT is usually ...Studies point to novel target for treating arrhythmias
... The researchers examined the heart rhythms of mice expressing various troponin mutants that cause HCM and showed that the mice develop ventricular tachycardia (a particular arrhythmia). The risk for this arrhythmia was directly related to the degree of calcium sensitization caused by the troponin mutation: ...Mitochondrial dysfunction and redox signaling in atrial tachyarrhythmia
... Researchers at the University Hospital of Magdeburg (Germany) have discovered that atrial tachycardia is associated with mitochondrial dysfunction and oxidative stress followed by the activation of the NF-kB signalling pathway with induction of NF-kB ...Fish oil -- helpful or harmful?
... such as men with stable angina. The same may also be true for patients with implantable cardioverter defibrillators who have a history of ventricular tachycardia and who are not taking antiarrhythmic medications. Fish oils have promise as beneficial in cardiovascular disease but our work highlights our gaps ...University of Pittsburgh cardiologists identify new cardiac arrest gene
... lead to less current flow and shorter heart beats in a part of the heart. This puts patients at risk for rapid heart rhythms such as ventricular tachycardia and fibrillation. Symptoms often present with no warning, and the seemingly healthy patient passes out and/or suffers a sudden cardiac arrest from an ...Engineered heart tissue offers insights into irregular heartbeats, defibrillator failure
... to understand the characteristics of ventricular tachycardia -- a condition characterized by abnormally fast ... death can result within minutes. "Ventricular tachycardia and fibrillation are the leading causes of sudden ... engineered tissues as would occur in ventricular tachycardia and attempted to halt it with pace-setting ....Researchers link two more genes to sudden infant death syndrome
... gene. RyR2 was targeted because of its involvement in a distinct genetic heart rhythm disease known as catecholaminergic polymorphic ventricular tachycardia (CPVT). "For a parent whose infant died suddenly and mysteriously even five years ago, we were essentially unable to provide them with a cause and ...Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
... with paroxysmal supraventricular tachycardia (PSVT). PSVT is a condition characterized ... for the treatment of paroxysmal supraventricular tachycardia in Q1 2009. Duska's CDP-1050 is expected to ... for the treatment of paroxysmal supraventricular tachycardia and the anticipated results of the trial, Duska's ...Cordex Pharma Forms Heart Failure Medical Advisory Board
... a Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia in 2009. Cordex's CDP-1050 is also expected to commence a Phase 2 ... Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia and the anticipated results of the trial, and CDP-1050's expected ...Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29
... a Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia early in 2009. Cordex's CDP-1050 is also expected to commence a Phase 2 ... Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia and the anticipated results of the trial, CDP-1050's expected commencement ...Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment
... is a proposed product for the termination of paroxysmal supraventricular tachycardia (PSVT). The bradycardic effect of ATP, in particular its blockade of ... patients presenting to the emergency room with paroxysmal supraventricular tachycardia (PSVT) should be sufficient to demonstrate clinical safety and efficacy, ...Cordex Completes Production of ATPace(TM) Clinical Trial Material
... Research, Inc. The CTM will be used in the planned clinical trials for the acute treatment of patients presenting with paroxysmal supraventricular tachycardia (PSVT) in the emergency room. Several formulations of ATP have been used in Europe for over five decades as the drug of choice for the acute ...Stereotaxis Showcases Advancements for Remote Magnetic Ablations
... partnered magnetic irrigated catheter, now available in Europe, is widely recognized as the gold standard for complex ablations such as ventricular tachycardia and complex left atrial arrhythmias. European clinicians have treated more than 600 patients with the magnetic irrigated catheter, with extremely ...Braemar Introduces the ER920W Wireless Cardiac Arrhythmia Monitor
... with embedded algorithms that automatically detect, record and immediately transmit asymptomatic events such as atrial fibrillation, bradycardia, tachycardia and cardiac pause. A photo of the ER920W is available at http://www.biotelinc.com/images/BraemarER920W.jpg . Braemar, Inc., designs, develops, ...CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection
... Less frequent side effects reported in patients administered Adenoscan include second and third degree AV block, fatal cardiac arrest, ventricular tachycardia and nonfatal myocardial infarction. For full prescribing information, please visit http://www.adenoscan.com . About CV Therapeutics CV ...Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
... Ranexa compared to placebo in the MERLIN TIMI-36 study. Patients receiving Ranexa had a 37 percent reduction in their relative risk of ventricular tachycardia lasting eight beats or more (p<0.001) and there were fewer episodes of sudden cardiac death observed in patients taking ranolazine (56) than in ...